Personalized gene therapy for ALS linked to TARDBP
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a personalized medicine approach for people with ALS caused by changes in the TARDBP gene. The treatment uses a custom-made molecule to target the genetic cause and may help slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed genetic diagnosis of a neurological disorder (likely ALS) caused by a TARDBP gene change.
- You are able to travel to the study site for visits and follow-ups.
- You are willing to provide access to your medical records.
- You have not used an investigational drug within a certain time before starting (less than 5 half-lives).
- You have no other condition that, in the doctor's opinion, would prevent you from completing the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers a custom-made treatment for people with ALS caused by a TARDBP gene mutation. It uses a personalized medicine approach to target the specific genetic cause of the disease.
This study aims to better understand ALS by looking at your genes, biomarkers, and stem cells. It may help develop treatments that are personalized to you.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This trial tests a new gene therapy called SNUG01 for adults with ALS. It aims to see if the treatment is safe and can slow the disease. You may be eligible if you are diagnosed early (within 2 years) and have good breathing function.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
This trial tests a personalized medicine approach for people with a specific genetic form of ALS caused by changes in the CHCHD10 gene. A custom-designed antisense oligonucleotide (a type of genetic therapy) is used to target the underlying cause of the disease.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.